Tae‐You Kim

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology · 2021 · 1.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Sae‐Won Han, Tae‐You Kim, Pil Gyu Hwang et al. · Journal of Clinical Oncology · 2005 · 775 citations · Full text

Medicine, Oncology, Pharmacology +17

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2021 · 319 citations

Medicine, Oncology, Pharmacology +10